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Editorial on the Research Topic
HSPs—Ambiguous Mediators of Immunity
Heat shock proteins (HSPs) were discovered as polypeptides induced by stress that can be found 
in all kingdoms of cellular organisms. Their functions were, a first enigmatic and these proteins 
were thus classified by molecular weight, as in—Hsp27, Hsp70, Hsp90, Hsp110 (1). More recently, 
each of these size-classified molecules has attributed a role in protein folding, and they thus came 
to be known, as a class, as molecular chaperones—deterrents of unsuitable interactions between 
intracellular proteins (2). However, the HSPs possess properties beyond chaperoning. Indeed, their 
discovery in the extracellular spaces suggested roles in intercellular signaling and in the convoluted 
regulation of the immune responses.
A number of lines of investigation triggered interest in HSPs as mediators of immunity. Srivastava 
and others found that the molecular chaperone properties of HSPs could be harnessed in cancer 
vaccine design (3–5). They emphasized the role of HSPs in capturing tumor antigens and permit-
ting their uptake and processing by antigen-presenting cells (APCs) prior to activation of cytotoxic 
lymphocytes. Others suggested that HSPs could behave like endogenous danger signals when flood-
ing into the extracellular microenvironment after cell death (6). In another line of investigation, 
investigators studied the role of mycobacterial Hsp65 and Hsp70 in suppression of autoimmune 
diseases such as arthritis, diabetes, and prolongation of tissue grafts [Borges et al.; (7, 8)]. HSPs were 
thus implicated in contrasting and apparently opposed aspects of immunity.
The current volume contains articles dealing with these aspects of HSP biology. Four articles 
describe various roles of HSPs in tumor immunity and anticancer vaccine construction. In chapter 1, 
Zuo et al. describe tumor immunity strategies built around the “large HSPs”—Hsp110 and GRP170. 
These larger HSPs possess chaperoning power of remarkable strength leading to high avidity for 
antigens and effective vaccines. Shevtsov and Multhoff in chapter 4 review in detail Hsp70 and Hsp90 
vaccines and their effectiveness in tumor therapy. The biological properties of Hsp90 are further 
discussed in chapter 5 by Tamura et al., emphasizing the role of this molecule in permitting antigens 
to cross plasma membranes, enter cells by endocytosis and cross the endosomal wall to the sites of 
antigen processing and acquisition by MHC Class I molecules. Most studies have indicated a role for 
surface receptors in mediating effects of extracellular HSPs. Murshid et al. in chapter 7 stress the role 
of scavenger receptors in the immune functions of such HSPs, concentrating on SRECI/SCARF1 as 
an avid binder of most of the HSPs.
Four additional chapters concentrate on the immunoregulatory properties of HSPs, particu-
larly emphasizing study of mycobacterial chaperones. In chapter 2, Manon et al. concentrate on 
mycobacterial Hsp70 and describe the generation of the first TCR transgenic mouse recognizing 
an anti-inflammatory Treg (regulatory T cell)-inducing Hsp70 peptides. The aim was to provide 
a model system for discovery of the mechanisms underlying generation of Hsp70-reactive 
CD4+CD25+ Treg and mediation of immunomodulation. In chapter 6, Moudgil et  al. describe 
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their interesting studies of the role of mycobacterial Hsp65 in 
controlling adjuvant arthritis in rodent models and potential 
development of novel treatments based on these findings. Along 
similar lines Borges et  al. describe studies showing a potent 
role for mycobacterial HSPs in regulating alloimmunity and 
improving survival of tissue grafts. Finally, the O’Brien group 
(chapter 8) describes roles for the small HSP—Hsp27 in attenu-
ating atherogenesis and other events in the extracellular spaces 
and in the circulation.
Finally, Calderwood et al. in chapter 3 attempt to synthesize 
some of theses apparently contrasting immunostimulatory and 
immunoregulatory effects of HSPs and develop an integrated 
understanding of potential sequela of HSPs encountering mac-
rophages or dendritic cells.
Thus, from the analysis contained in this collection of articles, 
we appear to have come a long way in past 30 years in understand-
ing “the other face of HSP biology”—the various families of HSPs 
escaping to the extracellular milieu and influencing immunity. 
However, much remains to be learned in terms of the recognition 
of HSPs by receptors on APC, in cell signaling and in understand-
ing how these events are influenced by tissue context. In addition, 
the complex pathways undertaken by HSP-chaperoned peptides 
in the intracellular milieu and their influence on antigen presen-
tation remain to be fully characterized. In terms of translation 
of HSP research to disease treatment, promising approaches to 
cancer immunotherapy, treatment of inflammatory disease such 
as arthritis and survival of tissue transplants appear to beckon. 
This area of HSP biology thus appears to have rich promise for 
the future.
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